Skip to main content

Table 5 List of additional drug modalities in the modified ITT population

From: The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: a multicenter, randomized, open-label trial

Other Treatments received during study n (%)

Steroid + Azithromycin (N = 116)

Azithromycin (N = 110)

Lopinavir/Ritonavir (N = 110)

Total (N = 336)

P-value

Oral steroid

6 (5.17)

11 (10.0)

16 (14.6)

33 (9.8)

0.118

Intravenous steroid

8 (6.9)

15 (13.6)

6 (5.5)

29 (8.6)

0.032

Steroid pulse therapy

12 (10.3)

10 (9.1)

3 (2.7)

25 (7.4)

0.055

Interferone

1 (0.9)

1 (0.9)

0 (0)

2 (0.6)

0.578

NSAID

8 (6.9)

10 (9.1)

20 (18.2)

38 (11.3)

0.038

Anticoagolant

61 (52.6)

63 (57.3)

69 (62.7)

193 (57.4)

0.881

Bronchodilator

21 (18.1)

24 (21.8)

30 (27.3)

75 (22.3)

0.287

Plasmapheresis

4 (3.5)

1 (0.9)

3 (2.7)

8 (2.4)

0.386

Favipiravir

1 (0.9)

0 (0)

1 (0.9)

2 (0.6)

0.610

Hyperimmune plasma

4 (3.5)

0 (0)

2 (1.8)

6 (1.8)

0.141

CinnoRA

7 (6.0)

6 (5.5)

4 (3.6)

17 (5.1)

0.547

Hemoperfiosion

0 (0)

1 (0.9)

2 (1.8)

3 (0.9)

0.354

Actemra

0 (0)

1 (0.9)

3 (2.7)

4 (1.2)

0.163